Thousand Oaks, California-headquartered Amgen Inc. (AMGN) discovers, develops, and manufactures revolutionary medicines geared toward enhancing the lives of thousands and thousands. With a market cap of $159.6 billion, Amgen has been a pioneer within the biotechnology business for over 40 years. Its portfolio consists of therapies for most cancers, coronary heart illness, osteoporosis, inflammatory illnesses, and uncommon circumstances.
Whereas Amgen has lagged behind the broader market over the previous 52 weeks, it has considerably outperformed it in 2025. AMGN inventory has dropped 11.5% over the previous 52 weeks and gained 13.9% in 2025, in comparison with the S&P 500 Index’s ($SPX) 14.5% features over the previous yr and 6.1% returns on a YTD foundation.
Narrowing the main target, Amgen has carried out barely higher than the Well being Care Choose Sector SPDR Fund’s (XLV) 13.3% decline over the previous yr and 4.7% drop in 2025.
Amgen’s inventory costs noticed a marginal drop within the buying and selling session after the discharge of its Q1 outcomes on Might 1; nevertheless, its efficiency remained sturdy throughout the quarter. Pushed by new product launches and elevated demand for its present merchandise, the corporate’s general topline for the quarter surged 9.4% year-over-year to $8.2 billion, exceeding Avenue expectations by 2.5%. Moreover, its adjusted EPS soared 23.7% year-over-year to $4.90, surpassing the consensus estimates by 17.8%.
For the complete fiscal 2025, ending in December, analysts count on Amgen to ship an adjusted EPS of $20.88, up 5.2% year-over-year. On a extra optimistic word, the corporate has a stable earnings shock historical past. It has surpassed the Avenue’s bottom-line projections in every of the previous 4 quarters.
The inventory has a consensus “Reasonable Purchase” ranking general. Of the 32 analysts overlaying the inventory, opinions embody 12 “Sturdy Buys,” two “Reasonable Buys,” 15 “Holds,” one “Reasonable Promote,” and two “Sturdy Sells.”
This configuration is barely much less bullish than three months in the past, when 13 analysts gave “Sturdy Purchase” suggestions.
On Jul. 27, Piper Sandler analyst David Amsellem reiterated an “Chubby” ranking on AMGN and maintained a value goal of $328.
Amgen’s imply value goal of $316.07 suggests a 6.5% upside potential. In the meantime, the Avenue-high goal of $400 represents a major 34.7% premium to present value ranges.
On the date of publication, Aditya Sarawgi didn’t have (both immediately or not directly) positions in any of the securities talked about on this article. All info and knowledge on this article is solely for informational functions. This text was initially revealed on Barchart.com